Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humira in Giant Cell Arteritis (HECTHOR)
NCT00305539Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2006
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in giant cell arteritis (GCA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Percentage of patients with corticosteroid dose <= 0.1 mg/kg at 26 weeks. Started May 2006; status: completed.
02
Drugs
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT00305539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305539.